cyrilzakka/clinical-trials huggingface dataset:
The Diagnosis and Treatment Pattern of CKD in Patients With Cardiovascular Disease- a National Cross-sectional Study

The goal of this observational study is to learn about in a total of approximately 2000 patients with cardiovascular disease recruited from about 25 participating sites in China with eGFR\<60 ml/min/1.73 m2 and/or UACR\>30 mg/g at least twice 3 months apart within the previous 12 months who had been hospitalized in the cardiology department within the previous 12 months. The main questions it aims to answer are:

* To estimate the diagnosis rate of CKD in patients with cardiovascular disease and laboratory evidence of CKD
* To describe the CKD awareness and treatment pattern in patients with cardiovascular disease and laboratory evidence of CKD.
* To describe the socio-demographic and clinical characteristics of CKD in patients with cardiovascular disease and laboratory evidence of CKD

Participants will be invited to undergo a baseline visit, and the demographics, lifestyle factors, clinical characteristics, and laboratory tests will be collected.


Eligibility Criteria:
Inclusion Criteria:

1. Female and/or male aged ≥18 years
2. Admitted to the cardiology department with diagnosed cardiovascular disease within the previous 12 months
3. Participants with eGFR\<60 ml/min/1.73 m2 and/or UACR\>30 mg/g at least twice 3 months apart within the previous 12 months

Exclusion Criteria:

1. Participants with known eGFR\<20 ml/min/1.73 m2 or undergoing dialysis or kidney transplantation
2. Pregnant or lactating women
3. Exposure to contrast medium or other reason leading to potential acute kidney injury since the baseline examination of eGFR/UACR
4. Patients who were participating in or had participated in any other clinical trial within the previous 12 months
Sublingual Microcirculation of Healthy Volunteers by Using the Third Generation Microcirculation Video Microscope

This study will enroll 150 healthy volunteers, and the grouping is as follows: group 20-39 (30 males and 30 females); group 40-59 (30 males and 30 females); and group 60-79 (15 males and 15 females). The sublingual microcirculation will be examined with the incident dark field video microscope (Cytocam，Braedius Battery Powered Transilluminator). The study aims to compare the differences of microcirculation among the three groups and between genders.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers aged from 20 to 79 years old
* BMI ranged from 18.5 to 27 kg/m2

Exclusion Criteria:

* Systolic blood pressure \> 140 mm Hg, diastolic blood pressure \> 95 mm Hg, or systolic blood pressure \< 90 mm Hg at enrollment
* Body temperature \> 37.5 ℃ or \< 35.5 ℃ at enrollment
* had been diagnose with any one of the following diseases

  * hypertension
  * diabetes mellitus
  * peripheral arterial occlusive disease
  * coronary arterial disease
  * liver cirrhosis
  * chronic kidney disease
  * stroke
  * anemia
  * asthma
  * chronic bronchitis
  * any metabolic diseases
  * any hematologic disease
  * uncured cancer
  * chronic uncontrolled infection
  * other disease may limit daily activities
  * non-native speakers
Clinical Trial to Evaluate the Endoscopic Ultrasound Guided Celiac Plexus Block for Treatment of Pain in Chronic Pancreatitis

AIM: To compare pain relief in patients randomly assigned to endoscopic ultrasound-guided celiac ganglia block (EUS-CGB) vs standard endoscopic ultrasound-guided celiac plexus block (EUS-CPB).

METHODS: This is a single-center, double-blind, randomized parallel-group study to assess the efficacy of EUS-CPB vs. EUS-CGB in patients with painful chronic pancreatitis.

Inclusion criteria include: age\>18 yrs, ability for informed consent, chronic daily pancreatic-type abdominal pain.

Exclusion criteria include: pregnancy, malignancy, recent acute pancreatitis (within 2 months), elevated INR (\>1.5) or low platelet count (\<75 cells/mm3), allergy to eggs or "caine" anesthetics.

Eligibility Criteria:
Inclusion Criteria:

* patients with chronic pancreatitis and referred for EUS-guided celiac plexus block with: age\>18 yrs, ability for informed consent, chronic daily pancreatic-type abdominal pain.

Exclusion Criteria:

* pregnancy, malignancy, recent acute pancreatitis (within 2 months), elevated INR (\>1.5) or low platelet count (\<75 cells/mm3), allergy to eggs or "caine" anesthetics.
A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

The study is designed to test the urate-lowering effect, safety, and tolerability of AC-201CR in an initial dosing period, followed by the addition of a ULT to test the efficacy and safety of the combination and prophylaxis of gout flares during ULT.

AC-201CR is a control released formulation of AC-201 that in previous clinical studies showed potential dual effects in both reducing serum uric acid (sUA) and gout flares. The mechanism of action of AC-201 includes the inhibition of the production and activity of caspase-1 and interleukin-1β (IL-1β), and selective inhibition of re-absorption transporters in the kidney. The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit while avoiding acute gout flares. However, the initiation of urate-lowering therapy (ULT) increases the occurrence of acute gouty arthritis flares. IL-1β plays a key role in mediating this inflammatory response.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female age 20 to 65 years, inclusive.
2. Meets ≥6 of the 12 American College of Rheumatology preliminary criteria (1977) for the classification of acute arthritis of primary gout (Appendix 2), OR have proven tophus or documented monosodium urate (MSU) crystals in the joint fluid.
3. Serum uric acid ≥7.5 mg/dL and ≤10 mg/dL at screening with ≥1 gouty arthritis flare within one year prior to screening, OR serum uric acid ≥9 mg/dL and ≤10 mg/dL at screening with or without prior gout flares.

Exclusion Criteria:

1. Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 2 weeks prior to screening.
2. Occurrence of a gouty arthritis flare within 1 week prior to screening or during the screening period through baseline.
3. Use of colchicine within 1 week prior to screening.
4. Use of Glucocorticoids, NSAIDs or COX-2 inhibitors within 1 week prior to screening.
5. Allergy, contraindication, or intolerance to febuxostat.
6. Severe renal impairment.
7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration \>2 times the upper limit of laboratory normal range (\>2x ULN) at screening.
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin) and Pegasys (peginterferon alfa-2a). Patients will receive Copegus 1000 mg or 1200 mg orally daily and Pegasys 180 mcg subcutaneously weekly. Anticipated time on study treatment, depending on virological response, will be 48 or 72 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Chronic hepatitis C, genotype 1
* Treatment-naïve or patients who relapsed or failed to respond to previous combination therapy with interferon and ribavirin
* Detectable HCV-RNA
* Fertile males and females of child-bearing potential must agree to use two forms of contraception during treatment and for 6 months after treatment end

Exclusion Criteria:

* Pregnant or breast-feeding women
* Male partners of pregnant women
* History or evidence of a medical condition associated with chronic liver disease other than HCV
* Co-infection with active hepatitis A, hepatitis B and/or HIV virus
* Hepatocellular carcinoma
* History or evidence of oesophageal varices or other conditions consistent with decompensated liver disease
* Anemia
* Any patient with increased baseline risk for anemia (e.g. thalassemia, spherocyctosis, history of GI bleeding)
* History or evidence of significant cardiovascular disease
* Kidney disease
* Severe retinopathy
* History of severe psychiatric disease, especially depression
* Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) \</= 6 months prior to first dose of study drug
The Clinical Applications of D-type Parastomal Hernia Repair Surgery

During the period from February 2018 to February 2022, a study was conducted on patients with parastomal hernia.There were 23 patients who underwent repair surgery for D-type colostomy hernia, while 68 patients underwent traditional laparoscopic repair surgery for hernia.The inclusion criteria were: (1) preoperative diagnosis of parastomal hernia by CT scan; (2) underwent laparoscopic repair surgery or combined laparoscopic repair with abdominal wall and stoma reconstruction surgery.The exclusion criteria were: (1) occurrence of tumor recurrence and/or new tumors during the follow-up period; (2) death or loss to follow-up during the follow-up period.


Eligibility Criteria:
Inclusion Criteria:

(1) preoperative diagnosis of parastomal hernia by CT scan; (2) underwent laparoscopic repair surgery or combined laparoscopic repair with abdominal wall and stoma reconstruction surgery.

Exclusion Criteria:

(1) occurrence of tumor recurrence and/or new tumors during the follow-up period; (2) death or loss to follow-up during the follow-up period.
Effect of Meal on Portal and Esophagus Variceal Pressure

The reason why esophagus varices suddenly rupture and start to bleed is unclear. Food intake increase the hepatic blood flow and the portal pressure, but it is yet unknown if there is also an increase in variceal pressure. The aim of this study is to evaluate the efficacy of a meal on variceal pressure with a non invasive endoscopic measurement device, and compare it with portal pressure.


Eligibility Criteria:
Inclusion Criteria:

* Large Esophageal varices

Exclusion Criteria:

* Treatment with beta-blocking agents
* Respiratory diseases that contradict endoscopy
* Gastric-retention
* Former gastric resection
* Resent sclerotherapy or former banding
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated.

Only Phase 1 of the study was enrolled and the study did not proceed into Phase 2.


Eligibility Criteria:
Inclusion Criteria:

* Known diagnosis of active cancer that is not considered cured or disease free.
* Confirmed COVID-19 infection as per World Health Organization (WHO) criteria with suspected pneumonia requiring hospitalization and oxygen saturation \< 94% on room air or requires supplemental oxygen.
* Adequate hematological, hepatic and renal function as would be medically expected of a cancer patient population.
* Able to swallow and absorb oral medications.

Exclusion Criteria:

* Current active treatment with medications contraindicated for receipt of investigational product.
* Require chemotherapy or urgent systemic therapy for active cancer that cannot be withheld.
* No remaining available therapies for advanced or metastatic malignancies.
* Participation in another clinical study with therapeutic intent for COVID-19
* Require artificial ventilation at screening.
* Life expectancy less than 6 months.
* Medical conditions that make it unsafe to receive investigational product (for example, heart attack in the last 6 mos, unstable angina, uncontrolled arrhythmia, heart failure class 3/4, QTC interval \> 480 msec; known bleeding disorders, stroke or intracranial hemorrhage in the last 6 mos; active HBV, HCV or history of HIV; GI malabsorption syndrome, small bowel resection, poorly controlled IBS; untreated/actively progressing known CNS lesions).
* Receipt of radiation therapy to the lung or mediastinum for treatment of COVID-19
Retinal Fundus Camera Evaluation

Establish a normal baseline setting configuration for image capture using the Topcon TRC-NW400 non-mydriatic retinal camera.

Establish a normal baseline setting configuration for image capture using the Topcon TRC-NW400 non-mydriatic retinal camera. While also comparing the images to other manufacturer's retinal cameras

Eligibility Criteria:
Inclusion Criteria:

* Subjects with no known ocular diseases

Exclusion Criteria:

* Subjects with known ocular diseases
Canrenone Effects on Cardiovascular Mortality in Patients With Congestive Heart Failure (the Coffee-it Study)

To evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with congestive heart failure and preserved systolic function after 12 years of evaluation.

The investigators will verify patients with cardiac heart failure (CHF) and preserved systolic function and each patient must have all clinical evaluation through basal measurements of blood pressure, heart rate, biochemical tests, and color Doppler echocardiographic parameters for at least 12 years.

The investigators will evaluate the effects of an aldosterone antagonist as canrenone compared to a group without canrenone and the investogators will verify how many patients reported cardiovascular mortality or will survive.

Eligibility Criteria:
Inclusion Criteria:

* patients with CHF
* preserved systolic function (FE ≥ 45%)

Exclusion Criteria:

* severe hypertension identified by blood pressure ≥180/110 mmHg
* patients with impaired systolic function (FE \< 45%)
* history of active hepatitis or cirrhosis
* impaired renal function
* hyperpotassemia
* diabetes
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.

This is a Phase IIb, global, randomised, parallel-group, double-blind, placebo-controlled, multi-centre, reduced factorial study designed to evaluate the efficacy, safety and tolerability of treatment with AZD9550 and AZD6234 in combination or as monotherapy in adults who are living with obesity or overweight with at least one of the following weight-related co-morbidities: hypertension, dyslipidemia or obstructive sleep apnoea. The study is composed of a screening period, a treatment period and a follow up period with participants expected to be in the study for approximately 47 weeks. The study will be conducted at around 60 sites and in approximately 7 countries with about, 360 participants will be randomly assigned to study intervention or placebo.

Eligibility Criteria:
Inclusion Criteria:

* Participant must be 18 to 75 years of age inclusive.
* BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity.
* A stable, self-reported body weight for 3 months prior to screening.
* Male and female participants: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
* Capable of giving signed informed consent.

Exclusion Criteria:

* History of any clinically important disease or disorder, which, in the opinion of the Investigator, may put the participant at risk.
* History or presence of GI, renal, hepatic disease.
* Previous or planned bariatric surgery or fitting of a weight loss device.
* Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma or Prader-Willi syndrome.
* History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control.
* HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or random glucose ≥ 200 mg/dL (11.1 mmol/L).
* Significant gastric and hepatobiliary disease.
* History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening.
* History of psychosis or bipolar disorder.
* History of major depressive disorder within the 2 years prior to screening or depression.
* Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the 3 months or 5 half-lives of the drug prior to screening.
* Vulnerable populations
RCT- LMA Supreme™ Versus the Spritztube® Tracheal Cannula in Anesthetized Adult Patients

The study compares the LMA Supreme™ versus the Spritztube® tracheal cannula in anesthetized adult patients.

The current randomized study is designed to assess the success placement of blind insertion using LMA Supreme™ , in comparison with the Spritztube® tracheal cannula.

In addition, time, number of attempts, easy insertion and the number of complications at insertion and removal will be assessed.

The investigators hypothesize that the LMA Supreme™ versus the Spritztube® tracheal cannula will similarly perform during anesthetized adult patients despite differences in their structural design.

A new extraglottic airway device, the Spritztube® \[tracheal cannula, Med Europe s.r.l\], was developed combining the ability to perform both EAD ventilation and oro-tracheal fibreoptic intubation using the same device. The Spritztube® consists of a silicone cannula with two low-pressure cuffs: a proximal cuff, designed to seal the pharynx cranially of the epiglottis and a distal cuff, designed to seal the oesophagus. The positioning of this device requires the aid of a spindle, that keep the cuffs on the same line and it is rigid enough to allow the passage through oropharynx tissue. That can be inserted blindly as extraglottic device or through the use of direct laryngoscopy or fibroscopy as tracheal cannula.

The current randomized study is designed to assess the success placement of blind insertion using LMA Supreme™ , in comparison with the Spritztube® tracheal cannula.

In addition, time, number of attempts, easy insertion and the number of complications at insertion and removal will be assessed.

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anaesthesiologists (ASA) physical status classification I, II, and III;
* Age \> 18 years
* Elective surgery in the supine position

Exclusion Criteria:

* Pregnancy
* Age \<18 years
* Not eligibility for surgery
* Predicted difficult airway management
* Positive history for esophageal or pharyngeal diseases
* Emergency surgery
Theta-burst Repetitive Transcranial Magnetic Stimulation (TBS) of the Right Inferior Frontal Gyrus for Treatment of Nicotine Dependence

The purpose of this research study is to examine the effects of theta-burst Transcranial Magnetic Stimulation on inhibitory control and smoking among adult cigarette smokers. In a double-blind, sham controlled trial, investigators will examine the effects of 12 sessions of cTBS on executive function and smoking behavior.


Eligibility Criteria:
Inclusion Criteria:

1. 18-65 yrs. of age
2. Smoke \> 5 cigarettes/day for ≥ 2 yrs, and expired carbon monoxide (CO) concentration of ≥ 8 ppm
3. English Fluency
4. Functional Vision (with corrective lenses as needed)

Exclusion Criteria:

1. Use of psychotropic and antiepileptic medications in the last month
2. Presence of an untreated illness or serious medical condition
3. History of major neurological illness
4. Contraindication to TMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \>15 min., implanted electronic device, metal in the head)
5. Any use of substances that lower seizure threshold
6. Current or past psychosis
7. Electroconvulsive therapy in last 6 months
8. Unstable cardiac disease or hypertension, severe renal or liver insufficiency, or sleep apnea
9. BAC greater than 0.0.
10. Positive urine pregnancy test
11. Any other concern that in the investigator's opinion would impact participant safety, study instruction compliance, or confound the interpretation of the study results
Vertebroplasty Using Real-Time, Fluoroscopy-Controlled, Catheter-Assisted, Low-Viscosity Cement Injection

Th low viscosity cement injection is safe in vertebroplasty procedure with Comparacle out come in pain relief.

Pain relief; Comparatle

Cement Leakage; Comparacle

Irradiation dose：less

Eligibility Criteria:
Inclusion Criteria:

* all painful fracture that can not be relieved by pain killer.

Exclusion Criteria:

* infection and malignancy in local region
Effects of a Motor Imagery Exercise Protocol in Patients With Fibromyalgia

The aim of this study was to evaluate the efficacy of a novel approach with a motor imagery-based exercise program versus conventional rehabilitative approach in fibromyalgia syndrome (FM): reduction of pain was set as the primary outcome.

Evidence about the therapeutic efficacy of exercise intervention programs in FM is still low and many authors suggested improving standardized exercise prescription for FM to achieve optimal results. In the literature, as an alternative approach, rehabilitative protocols in Group Music and Imagery seem to improve well-being and reduce anxiety in women with FM and suggest that Music and Imagery may help diminish pain intensity and depression. A rehabilitative approach should also consider the psychological and emotional aspects and, when possible, be accompanied by cognitive-behavioral therapy. The purpose of this research is to evaluate the possible efficacy of a novel approach with a motor imagery-based exercise program versus conventional rehabilitative approach in FM syndrome: the reduction of pain was set as the primary outcome as well as taking into account the patient's psychological and emotional condition. This study was designed as a double-blind, randomized, controlled trial.

Eligibility Criteria:
Inclusion Criteria:

* experienced widespread pain for more than 3 months
* pain with 4 kg/cm2 pressure at 11 or more of the 18 tender points
* aged 18 to 60 years
* pharmacological therapeutic regimen must have been stable for at least three months before

Exclusion Criteria:

* pregnant women
* pacemaker wearers
* overlapping painful conditions
* presence of autoimmune or hematologic diseases
* psychiatric disorders in pharmacological and psychological treatment
* other causes of chronic pain
* other diseases such as epilepsy, tumors, major neurological problems and diabetes
Laparoscopic Gastric Bypass as Metabolic Surgery in Obesity Class 1

Prospective study including Mexican patients diagnosed with type 2 diabetes and class 1 obesity, undergoing laparoscopic gastric bypass. The objective was to determine short, mid-and long-term outcomes (weight loss, metabolic, morbidity and diabetes remission). A subanalysis was included, based on preoperative usage of one (Group A) or more antidiabetics ± insulin (Group B).


Eligibility Criteria:
Inclusion criteria Any sex \>18 years-old \<60 years-old Class 1 obesity (BMI 30-34.9 kg/m2) Type-2 diabetes mellitus diagnosis (with or without medication) Submitted to laparoscopic gastric bypass

Exclusion criteria Other bariatric surgery Revisional surgery Incomplete charts